VYNE Reports Results of FMX114 in P-Ib Portion of a P-Ib/IIa Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Shots:
- The P-Ib portion of a P-Ib/IIa trial evaluates the preliminary safety, dermal tolerance & PK of FMX114 vs vehicle gel in 4 patients with AD for 2wks. The P-IIa segment of the study is expected to enroll ~25 patients with an expected result in Q2’22
- The results showed a mean reduction in ADSI score from baseline (-81.4% vs -54.3%) @2wk., 96.4% vs 45.8% mean reduction in worst pruritus NRS from baseline, the effect of FMX114 on reducing pruritus (itch) was also evaluated using the worst pruritus NRS
- FMX114 is the combination gel formulation of tofacitinib & fingolimod that addresses both the source & cause of inflammation in AD. The therapy was the 1st topical combination product for AD
Ref: Globe Newswire | Image: VYNE
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
